US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Conexeu Sciences Inc.

8.89

-0.5400-5.73%

Post-market: 8.71-0.1800-2.02%19:58 EDT

Volume:403.56K

Turnover:3.79M

Market Cap:237.88M

PE:-33.05

High:10.29

Open:9.42

Low:8.65

Close:9.43

52wk High:18.79

52wk Low:6.85

Shares:26.76M

Float Shares:15.56M

Volume Ratio:1.13

T/O Rate:2.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2690

EPS(LYR):-0.3104

ROE:--

ROA:--

PB:33.06

PE(LYR):-28.64

Loading ...

Overview Company News Filings

Conexeu Says CXU Preclinical Program Completes 12-Month P.r.o.o.f. Phase, Meets Objectives

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium

Conexeu Sciences CMO Presents on Extracellular Matrix Role in Tissue Regeneration at Laser & Cosmetic Surgery Symposium

Conexeu Sciences Announces Press Release Availability

Conexeu Sciences Completes 12-month Preclinical Study for CXU Tissue-restoration Platform

Conexeu Sciences Notifies Availability of Press Release

Conexeu Sciences Director Andrew Costa Files Initial Beneficial Ownership Statement

Alert Tagged to Multiple Companies from a Research Report Withdrawn

The Aesthetics Giants Just Confirmed “ozempic Face” is Real — and a Newly Public Regenerative Player Wants to Compete for It

THOMSON REUTERS

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences director Ana Lucia Bastiani-Posner files initial beneficial ownership statement

Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase

Conexeu Sciences Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target

MT Newswires Live

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Conexeu Sciences (CNXU) Stock Could Be 47.6% Undervalued After FDA Prep And Leadership Moves

Simply Wall St.

How Investors Are Reacting To Conexeu Sciences (CNXU) Bolstering Leadership For CXU Device Commercialization

Simply Wall St.

Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq Listing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CNXU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","market":"US","secType":"STK","nameCN":"Conexeu Sciences Inc.","latestPrice":8.89,"timestamp":1787342400000,"preClose":9.43,"halted":0,"volume":403557,"hourTrading":{"tag":"盘后","latestPrice":8.71,"preClose":8.89,"latestTime":"19:58 EDT","volume":23943,"amount":209340.3134,"timestamp":1787356735361,"change":-0.18,"changeRate":-0.020247,"amplitude":0.095613},"delay":0,"changeRate":-0.05726405090137849,"floatShares":15560742,"shares":26758300,"eps":-0.269,"marketStatus":"Market Closed","change":-0.54,"latestTime":"08-21 16:00:00 EDT","open":9.42,"high":10.2909,"low":8.65,"amount":3793799.0013,"amplitude":0.174008,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.269,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1779336000000,"exchange":"NASDAQ","adjPreClose":9.43,"preHourTrading":{"tag":"盘前","latestPrice":9.43,"preClose":9.43,"latestTime":"09:29 EDT","volume":1106,"amount":10341.905168,"timestamp":1787318970096,"change":0,"changeRate":0,"amplitude":0.04878},"postHourTrading":{"tag":"盘后","latestPrice":8.71,"preClose":8.89,"latestTime":"19:58 EDT","volume":23943,"amount":209340.3134,"timestamp":1787356735361,"change":-0.18,"changeRate":-0.020247,"amplitude":0.095613},"volumeRatio":1.1308731372545335},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNXU\",,,,,undefined,":{"symbol":"CNXU","floatShares":15560742,"roa":"--","roe":"--","lyrEps":-0.310358,"volumeRatio":1.1308731372545335,"shares":26758300,"dividePrice":0,"high":10.2909,"amplitude":0.174008,"preClose":9.43,"low":8.65,"week52Low":6.85,"pbRate":"33.06","week52High":18.7915,"institutionHeld":0,"latestPrice":8.89,"eps":-0.269,"divideRate":0,"volume":403557,"delay":0,"ttmEps":-0.269,"open":9.42,"prevYearClose":13.5,"prevWeekClose":8.9,"prevMonthClose":8.31,"prevQuarterClose":10.92,"fiveDayClose":8.9,"twentyDayClose":8.57,"sixtyDayClose":13.625},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNXU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNXU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNXU\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1782187200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNXU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNXU","date":"2026-08-21","current":-33.048327,"percent":0.688525,"low":-79.55424,"twenty":-61.471585,"median":-38.101134,"eighty":-33.023461,"high":-27.023926,"avg":-44.659029,"sd":15.019127,"marketCap":252331051},"quantilePoints":[{"date":"2026-05-22","current":-61.707651,"twenty":-61.707651,"median":-61.707651,"eighty":-61.707651,"marketCap":330278847},{"date":"2026-05-29","current":-54.672884,"twenty":-65.607461,"median":-64.327983,"eighty":-60.300698,"marketCap":292626553},{"date":"2026-06-05","current":-75.541118,"twenty":-76.3343,"median":-65.838806,"eighty":-60.437616,"marketCap":404319936},{"date":"2026-06-12","current":-57.26961,"twenty":-72.783868,"median":-65.815199,"eighty":-60.63119,"marketCap":306525051},{"date":"2026-06-18","current":-61.471585,"twenty":-72.022319,"median":-64.327983,"eighty":-56.504756,"marketCap":329015347},{"date":"2026-06-26","current":-37.989619,"twenty":-69.581868,"median":-61.589618,"eighty":-54.125211,"marketCap":273470132},{"date":"2026-07-02","current":-38.138306,"twenty":-67.458218,"median":-61.182094,"eighty":-40.651122,"marketCap":274540465},{"date":"2026-07-10","current":-36.837292,"twenty":-66.325102,"median":-57.26961,"eighty":-39.424451,"marketCap":265175050},{"date":"2026-07-17","current":-39.067602,"twenty":-65.494149,"median":-53.988293,"eighty":-38.257256,"marketCap":281230048},{"date":"2026-07-24","current":-34.012232,"twenty":-64.738738,"median":-41.558115,"eighty":-37.945013,"marketCap":244838719},{"date":"2026-07-31","current":-32.822733,"twenty":-64.002212,"median":-40.591647,"eighty":-36.004643,"marketCap":236276053},{"date":"2026-08-07","current":-31.484547,"twenty":-62.500833,"median":-39.94114,"eighty":-34.153485,"marketCap":226643055},{"date":"2026-08-14","current":-29.625955,"twenty":-61.660438,"median":-39.067602,"eighty":-32.859905,"marketCap":213263890},{"date":"2026-08-21","current":-35.053043,"twenty":-61.471585,"median":-38.101134,"eighty":-33.023461,"marketCap":252331051}],"updateTime":1787456181152},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNXU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660674844","title":"Conexeu Says CXU Preclinical Program Completes 12-Month P.r.o.o.f. Phase, Meets Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2660674844","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660674844?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:55","pubTimestamp":1787057729,"startTime":"0","endTime":"0","summary":"Conexeu says CXU preclinical program completes 12-month P.R.O.O.F. phase, meets objectivesConexeu disclosed completion of the 12-month P.R.O.O.F. phase in its CXU preclinical program for an ECM-based ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL5hTz5g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467389","title":"Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467389","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467389?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:30","pubTimestamp":1787056200,"startTime":"0","endTime":"0","summary":"Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU Platform Highli","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346816/0/en/conexeu-sciences-sees-a-new-category-forming-in-medical-aesthetics-as-research-turns-to-regeneration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658505916","title":"Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2658505916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658505916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:02","pubTimestamp":1786456969,"startTime":"0","endTime":"0","summary":"Conexeu Sciences, Inc. ( ($CNXU) ) just unveiled an announcement. Conexeu Sciences, a regenerative tissue platform specialist, is building its CXU ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/conexeu-highlights-ecm-based-regenerative-platform-ahead-of-2026-aesthetics-symposium?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/conexeu-highlights-ecm-based-regenerative-platform-ahead-of-2026-aesthetics-symposium?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658368918","title":"Conexeu Sciences CMO Presents on Extracellular Matrix Role in Tissue Regeneration at Laser & Cosmetic Surgery Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2658368918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658368918?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:32","pubTimestamp":1786451547,"startTime":"0","endTime":"0","summary":"Conexeu Sciences CMO presents on extracellular matrix role in tissue regeneration at Laser & Cosmetic Surgery symposiumConexeu will present at the Controversies & Conversations in Laser & Cosmetic Sur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8gBbQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","CNXU","NDAQ","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4588","BCDF","IE00BN0W2W23.USD","BK4139","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651110567","title":"Conexeu Sciences Announces Press Release Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2651110567","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651110567?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:31","pubTimestamp":1784032311,"startTime":"0","endTime":"0","summary":"Conexeu Sciences announces press release availabilityConexeu released an update on its CXU tissue-restoration platform, citing completion of a 12-month P.R.O.O.F. preclinical study.Focus is large-volu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLc1zG4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","CNXU","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649195853","title":"Conexeu Sciences Completes 12-month Preclinical Study for CXU Tissue-restoration Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2649195853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649195853?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:13","pubTimestamp":1783458831,"startTime":"0","endTime":"0","summary":"Conexeu Sciences completes 12-month preclinical study for CXU tissue-restoration platformConexeu completed its 12-month P.R.O.O.F preclinical study for the CXU platform, a key milestone ahead of plann","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL92bnq6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938802","title":"Conexeu Sciences Notifies Availability of Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649938802?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:01","pubTimestamp":1783429306,"startTime":"0","endTime":"0","summary":"Conexeu Sciences notifies availability of press releaseConexeu published a release reporting completion of its 12-month P.R.O.O.F preclinical program for the CXU platform.Results met study objectives ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL8HbHGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","CNXU","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BCDF","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378736","title":"Conexeu Sciences Director Andrew Costa Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378736","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647378736?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:15","pubTimestamp":1782728131,"startTime":"0","endTime":"0","summary":"Conexeu Sciences director Andrew Costa files initial beneficial ownership statementConexeu Sciences director Andrew Costa reported holding options to buy 50,000 common shares at USD 2.3 per share in a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL5Wm6lz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646980570","title":"Alert Tagged to Multiple Companies from a Research Report Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2646980570","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646980570?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:46","pubTimestamp":1782395175,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert tagged to multiple companies from a research report withdrawnAn alert from a Biotech Insider's research report on weight loss drugs was inadvertently published and tagged to AbbVie IncA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA8DWXYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","BK4585","LU0098860793.USD","LU0029864427.USD","LU0198837287.USD","IE00BDGV0183.EUR","LU1934455277.USD","LU2347655156.SGD","LU0289739343.SGD","SG9999015952.SGD","LU1244550577.SGD","LU0058720904.USD","LU1839511570.USD","LU2087621335.USD","LU2237443382.USD","ESTA","LU0511384066.AUD","LU2133065610.SGD","IE00B19Z3581.USD","LU2237443978.SGD","ABBV","LU1244550221.USD","IE00BBT3K403.USD","SG9999015945.SGD","LU1989771016.USD","LU0985320562.USD","LU1989772840.SGD","BK4082","IE0004445239.USD","LU1003077747.HKD","LU0795875169.SGD","LU0965509101.SGD","LU1551013425.SGD","IE00B19Z3B42.SGD","BK4588","LU1934455863.HKD","SG9999003800.SGD","CNXU","LU0965509283.SGD","LU0868494617.USD","LU1732799900.SGD","LU0114720955.EUR","SG9999011175.SGD","INMD","BK4550","LU2129689514.USD","IE00BFTCPJ56.SGD","LU0820561909.HKD","IE000BZT7R73.USD","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646163803","title":"The Aesthetics Giants Just Confirmed “ozempic Face” is Real — and a Newly Public Regenerative Player Wants to Compete for It","url":"https://stock-news.laohu8.com/highlight/detail?id=2646163803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646163803?lang=en_us&edition=fundamental","pubTime":"2026-06-25 21:04","pubTimestamp":1782392640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nTUA8DWXYW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015945.SGD","SG9999015952.SGD","SG9999003800.SGD","LU1934455863.HKD","LU1989772840.SGD","LU1989771016.USD","LU2237443382.USD","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","LU1551013425.SGD","LU1003077747.HKD","BK4550","IE0004445239.USD","LU2129689514.USD","LU0114720955.EUR","LU0203345920.USD","LU1244550221.USD","LU2347655156.SGD","BK4588","LU0965509101.SGD","LU2133065610.SGD","LU0868494617.USD","IE00BBT3K403.USD","LU0029864427.USD","LU0965509283.SGD","LU1839511570.USD","LU0198837287.USD","IE00B19Z3B42.SGD","LU1244550577.SGD","ESTA","IE00BDGV0183.EUR","BK4585","IE000BZT7R73.USD","LU2237443978.SGD","LU0820561909.HKD","LU0058720904.USD","LU0985320562.USD","ABBV","CNXU","LU0511384066.AUD","LU2087621335.USD","LU2468319806.SGD","BK4082","LU1732799900.SGD","LU0098860793.USD","SG9999011175.SGD","INMD","LU0795875169.SGD","LU1934455277.USD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646480850","title":"Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2646480850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646480850?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:30","pubTimestamp":1782390600,"startTime":"0","endTime":"0","summary":"Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Leadership team   Conexeu Sciences' leadership team celebrates the opening of the company's new...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317518/0/en/Conexeu-Sciences-Opens-Vancouver-R-D-Facility-to-Advance-Regenerative-Tissue-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645630558","title":"Conexeu Sciences director Ana Lucia Bastiani-Posner files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2645630558","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645630558?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:52","pubTimestamp":1782265935,"startTime":"0","endTime":"0","summary":"Conexeu Sciences director Ana Lucia Bastiani-Posner reported options to buy 50,000 common shares at USD 2.3, expiring Feb. 9, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL2vsrHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850972","title":"Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850972","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645850972?lang=en_us&edition=fundamental","pubTime":"2026-06-24 08:16","pubTimestamp":1782260190,"startTime":"0","endTime":"0","summary":"Conexeu Sciences disclosed a purchase by director, 10% owner Lynn Sebastian Purcell, held indirectly through OnePointTwo Capital Ventures.The filing shows an acquisition of 202,500 common shares at USD 0.8, lifting indirect holdings to 2,734,240 shares.OnePointTwo also bought 202,500 warrants for USD 0.001 each, exercisable at USD 2.3, with warrant holdings rising to 625,000.The filing also reports the exercise of 202,500 warrants at USD 0.8, leaving 625,000 warrants beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL5fjgcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Conexeu Sciences director, 10% owner Lynn Sebastian Purcell reports $162,000 common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645203029","title":"Conexeu Sciences Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645203029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645203029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:08","pubTimestamp":1782126480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNXU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:08 ET (11:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645502512","title":"HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2645502512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645502512?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:10","pubTimestamp":1782123035,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","ALGM","LQDA","GLW","KR","INTW","MRNX","LRCU","VC","DAL","MULL","FANG","INCY","BYD","KLAG","CNXU","AMAT","MTDR","MRNY","ARMK","MU","DFTX","NBIX","ALT","FTH","LGN","BILL","CHRD","FMC","LRCX","KLAC","DCH","ABVX","LINT","AGMB","MRK","BWIN","HCA","KMX","BWXT","AMRZ","APGE","INTC","AALG","FPS","AAL","MUU","DAR","ENPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645009430","title":"Conexeu Sciences (CNXU) Stock Could Be 47.6% Undervalued After FDA Prep And Leadership Moves","url":"https://stock-news.laohu8.com/highlight/detail?id=2645009430","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645009430?lang=en_us&edition=fundamental","pubTime":"2026-06-21 10:26","pubTimestamp":1782008788,"startTime":"0","endTime":"0","summary":"Conexeu Sciences (CNXU) has drawn fresh attention after expanding its board and executive team, including naming co founder David Bogart as Chief Commercial Officer, as it moves its CXU wound care platform toward FDA 510(k) preparation.\nSee our latest analysis for Conexeu Sciences.\nRecent appointments around the CXU platform come after a period of mixed trading, with a 7 day share price return of 17.63% and a 30 day share price return that declined 7.78% from a latest close of $13.28. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/conexeu-sciences-cnxu-stock-could-be-476-undervalued-after-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/conexeu-sciences-cnxu-stock-could-be-476-undervalued-after-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4139","BK4588","BK4585","CNXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644707093","title":"How Investors Are Reacting To Conexeu Sciences (CNXU) Bolstering Leadership For CXU Device Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2644707093","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644707093?lang=en_us&edition=fundamental","pubTime":"2026-06-18 17:37","pubTimestamp":1781775422,"startTime":"0","endTime":"0","summary":"Earlier in June 2026, Conexeu Sciences Inc. expanded its leadership bench by adding three seasoned directors, appointing co-founder David Bogart as Chief Commercial Officer, and bringing aesthetics expert Melinda Farina onto its advisory board, while also updating key board committees.\nThese changes, paired with recent progress on scaling manufacturing and regulatory preparation for its CXU wound care device, highlight Conexeu’s push to turn its regenerative tissue platform into a commercial...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/how-investors-are-reacting-to-conexeu-sciences-cnxu-bolsteri","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cnxu/conexeu-sciences/news/how-investors-are-reacting-to-conexeu-sciences-cnxu-bolsteri","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643523297","title":"Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2643523297","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643523297?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:15","pubTimestamp":1781612100,"startTime":"0","endTime":"0","summary":"A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization -- in one of medicine's most consequential frontiers.The move is less about any single hire than about what the collective résumé signals. For a company whose lead technology is still preclinical, building a board stocked with big-company financial and operating discipline is a statement of intent: that Conexeu means to be judged not as a science project, but as a company on a path to commercialization in one of the most consequential frontiers in medicine -- helping the body regenerate its own tissue. Whether it can deliver on that intent remains years from resolution, but the governance build-out is the kind of step investors in early-stage medtech tend to watch closely.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209908","title":"BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209908","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643209908?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:47","pubTimestamp":1781531243,"startTime":"0","endTime":"0","summary":"BRIEF-Conexeu Expands Board, Executive, And Advisory Leadership With Five Appointments Post Nasdaq ListingJune 15 (Reuters) - Conexeu Sciences Inc CNXU.O:CONEXEU EXPANDS BOARD, EXECUTIVE, AND ADVISORY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA88PTH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNXU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}